CGRB: Summary for - Yahoo! Canada Finance - Share Prices, Charts, News and more

	Sign In [New User? Sign Up]	Finance Home \|Help

Monday, November 23, 2009, 11:23am EST - Canadian Markets close in 4 hours and 37 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Cougar Biotechnology, Inc. (CGRB)

On Dec 31: 0.00 USD 0.00 (0.00%)

MORE ON CGRB

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

(NGM:CGRB) Delayed quote data

Last Trade:	0.00 USD
Trade Time:	Dec 31
Change:	0.00 (0.00%)
Prev Close:	N/A
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	38.50

Day's Range:	N/A - N/A
52wk Range:	16.35 - 45.00
Volume:	0
Avg Vol (3m):	435,814
Market Cap:	N/A
P/E (ttm):	N/A
EPS (ttm):	-2.53
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y

Add CGRB to Portfolio

Download Data

HEADLINES

•	[$$] JNJ Preview: Medical Devices Should Be the Highlight
	at RealMoney by TheStreet.com (Mon, Oct 12)

•	COUGAR BIOTECHNOLOGY, INC. Files SEC form 8-K, Changes in Control or Registrant, Change in Directors or Principal Off
	EDGAR Online (Thu, Jul 9)

•	[video] China Watch: Yongye Biotechnology
	at TheStreet.com (Wed, Jun 17)

•	Cougar's board recommends accepting J&J's offer
	at MarketWatch (Fri, Jun 5)

•	COUGAR BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events
	EDGAR Online (Mon, Jun 1)

•	OncoGenex Prostate Drug Extends Survival in Study
	at TheStreet.com (Sat, May 30)

•	Study: OncoGenex Prostate Drug Extends Survival
	at TheStreet.com (Sat, May 30)

•	OncoGenex Prostate Drug Extends Survival
	at TheStreet.com (Sat, May 30)

•	This Company Is Hot and Going Places
	at Motley Fool (Fri, May 29)

•	Pharma's Feeding Frenzy
	at CNBC (Thu, May 28)

More Headlines for CGRB...

ANALYST

EPS Est (next year) (Dec-07) :	-2.23
EPS Est (in 2 years) (Dec-08) :	-2.80
Avg Rec (current)*:	1.3
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Cougar Biotechnology, Inc., a development stage biopharmaceutical company, engages in the acquisition and development of therapeutics for the treatment of cancer.

Full Company Profile

Add to Portfolio

Email to a Friend

•